Episodic and electrical nervous system disorders caused by nonchannel genes

Annual Review of Physiology

Volumn 77, Issue , 2015, Pages 525-541

  Lee, Hsien Yang ^a   Fu, Ying Hui ^a   Ptáček, Louis J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Channelopathies; Epilepsy; Familial disorders; Migraine; Nonchannel causes of electrical diseases

Indexed keywords

CASEIN KINASE IDELTA; GLUCOSE TRANSPORTER 1; NOL3 PROTEIN; PROTEIN; PRRT2 PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; G PROTEIN COUPLED RECEPTOR; MASS1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MUSCLE PROTEIN; NERVE PROTEIN; NOL3 PROTEIN, HUMAN; PRRT2 PROTEIN, HUMAN;

ARTICLE; AUDIOGENIC SEIZURE; CONVULSION; DYSKINESIA; GENE; GENE MUTATION; HUMAN; MIGRAINE WITH AURA; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; MYOCLONUS; NEUROLOGIC DISEASE; NONCHANNEL GENE; NONHUMAN; PAROXYSMAL KINESIGENIC DYSKINESIA; PAROXYSMAL NONKINESIGENIC DYSKINESIA; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPSE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CASEIN KINASE IDELTA; DISEASE MODELS, ANIMAL; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MEMBRANE PROTEINS; MICE; MUSCLE PROTEINS; MUTATION; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SYNAPSES;

EID: 84922819992     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021014-071814     Document Type: Article

References (139)

1. Ptacek LJ, Fu YH. 2002. Molecular biology of episodic movement disorders. Adv. Neurol. 89:453-58
2. Ryan DP, Ptáček LJ. 2010. Episodic neurological channelopathies. Neuron 68:282-92
3. Kertesz A. 1967. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 17:680-90
4. Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, et al. 2004. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 63:2280-87
5. Lee HY, Huang Y, Bruneau N, Roll P, Roberson ED, et al. 2012. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 1:2-12
6. Swoboda KJ, Soong B, McKenna C, Brunt ER, Litt M, et al. 2000. Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology 55:224-30
7. Mount LA, Reback S. 1940. Familial paroxysmal choreoathetosis: preliminary report on a hitherto undescribed clinical syndrome. Arch. Neurol. Psychiat. 44:841-47
8. Bruno MK, Lee HY, Auburger GW, Friedman A, Nielsen JE, et al. 2007. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology 68:1782-89
9. Lance JW. 1977. Familial paroxysmal dystonic choreoathetosis and its differentiation from related syndromes. Ann. Neurol. 2:285-93
10. Bhatia KP. 2011. Paroxysmal dyskinesias. Mov. Disord. 26:1157-65
11. Charlesworth G, Bhatia KP,Wood NW. 2013. The genetics of dystonia: new twists in an old tale. Brain 136:2017-37
12. Weber YG, Lerche H. 2009. Genetics of paroxysmal dyskinesias. Curr. Neurol. Neurosci. Rep. 9:206-11
13. Mehta SH, Morgan JC, Sethi KD. 2009. Paroxysmal dyskinesias. Curr. Treat. Options Neurol. 11:170-78
14. Fuchs T, Ozelius LJ. 2011. Genetics of dystonia. Semin. Neurol. 31:441-48
15. Skradski SL,White HS, Ptáček LJ. 1998. Geneticmapping of a locus (mass1) causing audiogenic seizures in mice. Genomics 49:188-92
16. Skradski SL, Clark AM, JiangH,White HS, Fu YH, Ptáček LJ. 2001. A novel gene causing aMendelian audiogenic mouse epilepsy. Neuron 31:537-44
17. Klein BD, Fu YH, Ptacek LJ, White HS. 2005. Auditory deficits associated with the Frings Mgr1 (Mass1) mutation in mice. Dev. Neurosci. 27:321-32
18. Deleted in proof
19. Johnson KR, Zheng QY, Weston MD, Ptacek LJ, Noben-Trauth K. 2005. The Mass1frings mutation underlies early onset hearing impairment in BUB/BnJ mice, a model for the auditory pathology of Usher syndrome IIC. Genomics 85:582-90
20. Nakayama J, Hamano K, Iwasaki N, Nakahara S, Horigome Y, et al. 2000. Significant evidence for linkage of febrile seizures to chromosome 5q14-q15. Hum. Mol. Genet. 9:87-91
21. Deprez L, Claes LR, Claeys KG, Audenaert D, Van Dyck T, et al. 2006. Genome-wide linkage of febrile seizures and epilepsy to the FEB4 locus at 5q14.3-q23.1 and no MASS1 mutation. Hum. Genet. 118:618-25
22. Nakayama J, Fu YH, Clark AM, Nakahara S, Hamano K, et al. 2002. A nonsensemutation of the MASS1 gene in a family with febrile and afebrile seizures. Ann. Neurol. 52:654-57
23. Bonnet C, El-Amraoui A. 2012. Usher syndrome (sensorineural deafness and retinitis pigmentosa): pathogenesis, molecular diagnosis and therapeutic approaches. Curr. Opin. Neurol. 25:42-49
24. YanD, Liu XZ. 2010. Genetics and pathological mechanisms of Usher syndrome. J. Hum. Genet. 55:327-35
25. Besnard T, Vache C, Baux D, Larrieu L, Abadie C, et al. 2012. Non-USH2A mutations in USH2 patients. Hum. Mutat. 33:504-10
26. Ebermann I, Wiesen MH, Zrenner E, Lopez I, Pigeon R, et al. 2009. GPR98 mutations cause Usher syndrome type 2 in males. J. Med. Genet. 46:277-80
27. Garcia-Garcia G, Besnard T, Baux D, Vache C, Aller E, et al. 2013. The contribution of GPR98 and DFNB31 genes to a Spanish Usher syndrome type 2 cohort. Mol. Vis. 19:367-73
28. Hilgert N, Kahrizi K, Dieltjens N, Bazazzadegan N, Najmabadi H, et al. 2009. A large deletion in GPR98 causes type IIC Usher syndrome in male and female members of an Iranian family. J. Med. Genet. 46:272-76
29. Hmani-Aifa M, Benzina Z, Zulfiqar F, Dhouib H, Shahzadi A, et al. 2009. Identification of two new mutations in the GPR98 and the PDE6B genes segregating in a Tunisian family. Eur. J. Hum. Genet. 17:474-82
30. Le Quesne Stabej P, Saihan Z, Rangesh N, Steele-Stallard HB, Ambrose J, et al. 2012. Comprehensive sequence analysis of nine Usher syndrome genes in the UK National Collaborative Usher Study. J. Med. Genet. 49:27-36
31. WestonMD,LuijendijkMW,Humphrey KD,MollerC,KimberlingWJ. 2004. Mutations in theVLGR1 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II. Am. J. Hum. Genet. 74:357-66
32. Ebermann I, Phillips JB, Liebau MC, Koenekoop RK, Schermer B, et al. 2010. PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. J. Clin. Investig. 120:1812-23
33. McMillan DR, Kayes-Wandover KM, Richardson JA, White PC. 2002. Very large G protein-coupled receptor-1, the largest known cell surface protein, is highly expressed in the developing central nervous system. J. Biol. Chem. 277:785-92
34. Scheel H, Tomiuk S, Hofmann K. 2002. A common protein interaction domain links two recently identified epilepsy genes. Hum. Mol. Genet. 11:1757-62
35. Kalachikov S, Evgrafov O, Ross B, Winawer M, Barker-Cummings C, et al. 2002. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat. Genet. 30:335-41
36. Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, Saenz A, Poza JJ, et al. 2002. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum. Mol. Genet. 11:1119-28
37. Yagi H, Takamura Y, Yoneda T, Konno D, Akagi Y, et al. 2005. Vlgr1 knockout mice show audiogenic seizure susceptibility. J. Neurochem. 92:191-202
38. McMillan DR,White PC. 2004. Loss of the transmembrane and cytoplasmic domains of the very large G-protein-coupled receptor-1 (VLGR1 or Mass1) causes audiogenic seizures inmice. Mol. Cell. Neurosci. 26:322-29
39. GratiM, Shin JB, Weston MD, Green J, Bhat MA, et al. 2012. Localization of PDZD7 to the stereocilia ankle-link associates this scaffolding protein with the Usher syndrome protein network. J. Neurosci. 32:14288-93
40. McGee J, Goodyear RJ, McMillan DR, Stauffer EA, Holt JR, et al. 2006. The very large G-proteincoupled receptor VLGR1: a component of the ankle link complex required for the normal development of auditory hair bundles. J. Neurosci. 26:6543-53
41. Shin D, Lin S-T, Fu Y-H, Ptáček LJ. 2013. MASS1 regulates MAG expression via Gαs/Gαq-mediated PKA/PKC pathways. PNAS 110:19101-6
42. Shibasaki H, Hallett M. 2005. Electrophysiological studies of myoclonus. Muscle Nerve 31:157-74
43. Asmus F, Zimprich A, Tezenas Du Montcel S, Kabus C, Deuschl G, et al. 2002. Myoclonus-dystonia syndrome: ε-sarcoglycan mutations and phenotype. Ann. Neurol. 52:489-92
44. Zimprich A, GrabowskiM, Asmus F, Naumann M, Berg D, et al. 2001. Mutations in the gene encoding ε-sarcoglycan cause myoclonus-dystonia syndrome. Nat. Genet. 29:66-69
45. Russell JF, Steckley JL, Coppola G, Hahn AF, Howard MA, et al. 2012. Familial cortical myoclonus with a mutation in NOL3. Ann. Neurol. 72:175-83
46. Gulesserian T, Engidawork E, Yoo BC, Cairns N, Lubec G. 2001. Alteration of caspases and other apoptosis regulatory proteins in Down syndrome. J. Neural Transm. Suppl. 2001:163-79
47. Koseki T, Inohara N, Chen S, Nunez G. 1998. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. PNAS 95:5156-60
48. Shelke RR, Leeuwenburgh C. 2003. Lifelong caloric restriction increases expression of apoptosis repressor with a caspase recruitment domain (ARC) in the brain. FASEB J. 17:494-96
49. Chou JJ, Matsuo H, Duan H, Wagner G. 1998. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment. Cell 94:171-80
50. Zhou P, Chou J, Olea RS,Yuan J,WagnerG. 1999. Solution structure ofApaf-1CARDand its interaction with caspase-9 CARD: a structural basis for specific adaptor/caspase interaction. PNAS 96:11265-70
51. Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, et al. 2006. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation 113:1203-12
52. Engidawork E, Gulesserian T, Yoo BC, Cairns N, Lubec G. 2001. Alteration of caspases and apoptosisrelated proteins in brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 281:84-93
53. Nam YJ, Mani K, Ashton AW, Peng CF, Krishnamurthy B, et al. 2004. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol. Cell 15:901-12
54. Macerollo A, Mencacci NE, Erro R, Cordivari C, Edwards MJ, et al. 2014. Screening of mutations in NOL3 in a myoclonic syndromes series. J. Neurol. 261:1830-31
55. Eising E, de Vries B, Ferrari MD, Terwindt GM, van den Maagdenberg AM. 2013. Pearls and pitfalls in genetic studies of migraine. Cephalalgia 33:614-25
56. Weir GA, Cader MZ. 2011. New directions in migraine. BMC Med. 9:116
57. Zameel CaderM. 2013. The molecular pathogenesis of migraine: new developments and opportunities. Hum. Mol. Genet. 22:R39-44
58. de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. 2009. Molecular genetics of migraine. Hum. Genet. 126:115-32
59. Di Lorenzo C, Grieco GS, Santorelli FM. 2012. Migraine headache: a review of the molecular genetics of a common disorder. J. Headache Pain 13:571-80
60. Silberstein SD, Dodick DW. 2013. Migraine genetics: part II. Headache 53:1218-29
61. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, et al. 1996. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543-52
62. Terwindt G, Kors E, Haan J, Vermeulen F, van den Maagdenberg A, et al. 2002. Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch. Neurol. 59:1016-18
63. De FuscoM,Marconi R, Silvestri L, Atorino L, Rampoldi L, et al. 2003. Haploinsufficiency of ATP1A2 encoding theNa+/K+ pump α2 subunit associated with familial hemiplegic migraine type2. Nat. Genet. 33:192-96
64. Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, et al. 2003. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann. Neurol. 54:360-66
65. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, et al. 2005. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366:371-77
66. Vahedi K, Depienne C, Le Fort D, Riant F, Chaine P, et al. 2009. Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology 72:1178-83
67. Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, et al. 2013. Casein kinase Iδ mutations in familial migraine and advanced sleep phase. Sci. Transl. Med. 5:183ra156
68. Xu Y, Padiath QS, Shapiro RE, Jones CR, Wu SC, et al. 2005. Functional consequences of a CKIδ mutation causing familial advanced sleep phase syndrome. Nature 434:640-44
69. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. 2005. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell. Signal. 17:675-89
70. Knippschild U, Kruger M, Richter J, Xu P, Garcia-Reyes B, et al. 2014. The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Front. Oncol. 4:96
71. Charles AC, Baca SM. 2013. Cortical spreading depression and migraine. Nat. Rev. Neurol. 9:637-44
72. Contreras JE, Sanchez HA, Eugenin EA, Speidel D, Theis M, et al. 2002. Metabolic inhibition induces opening of unapposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. PNAS 99:495-500
73. Stout CE, Costantin JL, Naus CC, Charles AC. 2002. Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. J. Biol. Chem. 277:10482-88
74. Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR. 2003. Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J. Neurosci. 23:3588-96
75. Cooper CD, Lampe PD. 2002. Casein kinase 1 regulates connexin-43 gap junction assembly. J. Biol. Chem. 277:44962-68
76. Marquez-Rosado L, Solan JL, Dunn CA, Norris RP, Lampe PD. 2012. Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues. Biochim. Biophys. Acta 1818:1985-992
77. Saez JC, Berthoud VM, BranesMC, Martinez AD, Beyer EC. 2003. Plasma membrane channels formed by connexins: their regulation and functions. Physiol. Rev. 83:1359-400
78. Sarrouilhe D, Dejean C, Mesnil M. 2014. Involvement of gap junction channels in the pathophysiology of migraine with aura. Front. Physiol. 5:78
79. Solan JL, Lampe PD. 2009. Connexin43 phosphorylation: structural changes and biological effects. Biochem. J. 419:261-72
80. Lampe PD, Lau AF. 2004. The effects of connexin phosphorylation on gap junctional communication. Int. J. Biochem. Cell Biol. 36:1171-86
81. Solan JL, Lampe PD. 2005. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim. Biophys. Acta 1711:154-63
82. Lampe PD, Cooper CD, King TJ, Burt JM. 2006. Analysis of Connexin43 phosphorylated at S325, S328 and S330 in normoxic and ischemic heart. J. Cell Sci. 119:3435-42
83. Theis M, Jauch R, Zhuo L, Speidel D, Wallraff A, et al. 2003. Accelerated hippocampal spreading depression and enhanced locomotory activity inmice with astrocyte-directed inactivation of connexin43. J. Neurosci. 23:766-76
84. LeeHY, Xu Y, Huang Y, Ahn AH, AuburgerGW, et al. 2004. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum. Mol. Genet. 13:3161-70
85. Chen DH, Matsushita M, Rainier S, Meaney B, Tisch L, et al. 2005. Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds. Arch. Neurol. 62:597-600
86. Friedman A, Zakrzewska-Pniewska B, Domitrz I, Lee HY, Ptacek L, Kwiecinski H. 2009. Paroxysmal non-kinesigenic dyskinesia caused by the mutation of MR-1 in a large Polish kindred. Eur. Neurol. 61:39-41
87. Hempelmann A, Kumar S,Muralitharan S, Sander T. 2006. Myofibrillogenesis regulator 1 gene (MR-1) mutation in an Omani family with paroxysmal nonkinesigenic dyskinesia. Neurosci. Lett. 402:118-20
88. Rainier S, Thomas D, Tokarz D, Ming L, Bui M, et al. 2004. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch. Neurol. 61:1025-29
89. Yeh TH, Lin JJ, Lai SC, Wu-Chou YH, Chen AC, et al. 2012. Familial paroxysmal nonkinesigenic dyskinesia: clinical and genetic analysis of a Taiwanese family. J. Neurol. Sci. 323:80-84
90. Ghezzi D, Viscomi C, Ferlini A, Gualandi F, Mereghetti P, et al. 2009. Paroxysmal non-kinesigenic dyskinesia is caused by mutations of the MR-1 mitochondrial targeting sequence. Hum. Mol. Genet. 18:1058-64
91. Lee HY, Nakayama J, Xu Y, Fan X, Karouani M, et al. 2012. Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. J. Clin. Investig. 122:507-18
92. Gundelfinger ED, Fejtova A. 2011. Molecular organization and plasticity of the cytomatrix at the active zone. Curr. Opin. Neurobiol. 22:423-30
93. Kaeser PS. 2011. Pushing synaptic vesicles over the RIM. Cell. Logist. 1:106-10
94. Kaeser PS, Deng L, Fan M, Sudhof TC. 2012. RIM genes differentially contribute to organizing presynaptic release sites. PNAS 109:11830-35
95. NagaoM, Fujita Y, Sugimura T, Kosuge T. 1986. Methylglyoxal in beverages and foods: its mutagenicity and carcinogenicity. IARC Sci. Publ. 1986:283-91
96. Thornalley PJ. 1990. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem. J. 269:1-11
97. Thornalley PJ. 1993. The glyoxalase system in health and disease. Mol. Aspects Med. 14:287-371
98. Thornalley PJ. 1996. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 27:565-73
99. Shen Y, Lee HY, Rawson J, Ojha S, Babbitt P, et al. 2011. Mutations in PNKD causing paroxysmal dyskinesia alters protein cleavage and stability. Hum. Mol. Genet. 20:2322-32
100. Chen WJ,Lin Y, XiongZQ,WeiW,NiW, et al. 2011. Exome sequencing identifies truncatingmutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat. Genet. 43:1252-55
101. Cloarec R, Bruneau N, Rudolf G,Massacrier A, SalmiM, et al. 2012. PRRT2 links infantile convulsions and paroxysmal dyskinesia with migraine. Neurology 79:2097-103
102. Heron SE, Grinton BE, Kivity S, Afawi Z, Zuberi SM, et al. 2012. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am. J. Hum. Genet. 90:152-60
103. Lee YC, Lee MJ, Yu HY, Chen C, Hsu CH, et al. 2012. PRRT2 mutations in paroxysmal kinesigenic dyskinesia with infantile convulsions in a Taiwanese cohort. PLOS ONE 7:e38543
104. Meneret A, Grabli D, Depienne C, Gaudebout C, Picard F, et al. 2012. PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. Neurology 79:170-74
105. Okumura A, Shimojima K, Kubota T, Abe S, Yamashita S, et al. 2013. PRRT2 mutation in Japanese children with benign infantile epilepsy. Brain Dev. 35:641-46
106. Schubert J, Paravidino R, Becker F, Berger A, Bebek N, et al. 2012. PRRT2 mutations are the major cause of benign familial infantile seizures. Hum. Mutat. 33:1439-43
107. Wang JL, Cao L, Li XH, Hu ZM, Li JD, et al. 2011. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 134:3493-501
108. Gardiner AR, Bhatia KP, Stamelou M, Dale RC, Kurian MA, et al. 2012. PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology 79:2115-21
109. Heron SE, Dibbens LM. 2013. Role of PRRT2 in common paroxysmal neurological disorders: a gene with remarkable pleiotropy. J. Med. Genet. 50:133-39
110. Meneret A, Gaudebout C, Riant F, Vidailhet M, Depienne C, Roze E. 2013. PRRT2 mutations and paroxysmal disorders. Eur. J. Neurol. 20:872-78
111. Hedera P, Xiao J, Puschmann A, Momcilovic D, Wu SW, LeDoux MS. 2012. Novel PRRT2 mutation in an African-American family with paroxysmal kinesigenic dyskinesia. BMC Neurol. 12:93
112. Groffen AJ, Klapwijk T, van Rootselaar AF, Groen JL, Tijssen MA. 2013. Genetic and phenotypic heterogeneity in sporadic and familial forms of paroxysmal dyskinesia. J. Neurol. 260:93-99
113. Riant F, Roze E, Barbance C, Meneret A, Guyant-Marechal L, et al. 2012. PRRT2 mutations cause hemiplegic migraine. Neurology 79:2122-24
114. van Vliet R, Breedveld G, de Rijk-van Andel J, Brilstra E, Verbeek N, et al. 2012. PRRT2 phenotypes and penetrance of paroxysmal kinesigenic dyskinesia and infantile convulsions. Neurology 79:777-84
115. Stojilkovic SS. 2005. Ca2+-regulated exocytosis andSNAREfunction. Trends Endocrinol.Metab. 16:81-83
116. Zhao N, HashidaH, Takahashi N, Sakaki Y. 1994. Cloning and sequence analysis of the human SNAP25 cDNA. Gene 145:313-14
117. Hu K, Carroll J, Fedorovich S, Rickman C, Sukhodub A, Davletov B. 2002. Vesicular restriction of synaptobrevin suggests a role for calcium in membrane fusion. Nature 415:646-50
118. Sorensen JB, Matti U, Wei SH, Nehring RB, Voets T, et al. 2002. The SNARE protein SNAP-25 is linked to fast calcium triggering of exocytosis. PNAS 99:1627-32
119. Chin LS, Li L, Ferreira A, Kosik KS, Greengard P. 1995. Impairment of axonal development and of synaptogenesis in hippocampal neurons of synapsin I-deficient mice. PNAS 92:9230-34
120. Giovedi S, Vaccaro P, Valtorta F, Darchen F, Greengard P, et al. 2004. Synapsin is a novel Rab3 effector protein on small synaptic vesicles. I. Identification and characterization of the synapsin I-Rab3 interactions in vitro and in intact nerve terminals. J. Biol. Chem. 279:43760-68
121. Li L, Chin LS, Shupliakov O, Brodin L, Sihra TS, et al. 1995. Impairment of synaptic vesicle clustering and of synaptic transmission, and increased seizure propensity, in synapsin I-deficient mice. PNAS 92:9235-39
122. Dale RC,Grattan-Smith P, Fung VS, Peters GB. 2011. Infantile convulsions and paroxysmal kinesigenic dyskinesia with 16p11.2 microdeletion. Neurology 77:1401-2
123. Dale RC,Grattan-Smith P,NicholsonM, PetersGB. 2012. Microdeletions detected using chromosome microarray in children with suspected geneticmovement disorders: a single-centre study. Dev. Med. Child Neurol. 54:618-23
124. Lipton J, Rivkin MJ. 2009. 16p11.2-related paroxysmal kinesigenic dyskinesia and dopa-responsive parkinsonism in a child. Neurology 73:479-80
125. Weber A, Kohler A, Hahn A, Neubauer B, Muller U. 2013. Benign infantile convulsions (IC) and subsequent paroxysmal kinesigenic dyskinesia (PKD) in a patient with 16p11.2microdeletion syndrome. Neurogenetics 14:251-53
126. Mullen SA, Suls A, De Jonghe P, Berkovic SF, Scheffer IE. 2010. Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology 75:432-40
127. Suls A, Dedeken P,Goffin K, Van Esch H, Dupont P, et al. 2008. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporterGLUT1. Brain 131:1831-44
128. Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, et al. 2008. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J. Clin. Investig. 118:2157-68
129. Auburger G, Ratzlaff T, Lunkes A, Nelles HW, Leube B, et al. 1996. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. Genomics 31:90-94
130. Weber YG, Kamm C, Suls A, Kempfle J, Kotschet K, et al. 2011. Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology 77:959-64
131. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, et al. 1997. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J. Clin. Investig. 100:2842-48
132. Montel-Hagen A, Kinet S, Manel N, Mongellaz C, Prohaska R, et al. 2008. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 132:1039-48
133. De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. 1991. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N. Engl. J. Med. 325:703-9
134. Leen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, et al. 2010. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 133:655-70
135. Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, et al. 2004. GLUT1 deficiency and other glucose transporter diseases. Eur. J. Endocrinol. 150:627-33
136. Brockmann K. 2009. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev. 31:545-52
137. De Giorgis V, Veggiotti P. 2013. GLUT1 deficiency syndrome 2013: current state of the art. Seizure 22:803-11
138. Leen WG, Taher M, Verbeek MM, Kamsteeg EJ, van de Warrenburg BP, Willemsen MA. 2014. GLUT1 deficiency syndrome into adulthood: a follow-up study. J. Neurol. 261:589-99
139. Ptáček LJ. 2015. Episodic disorders: channelopathies and beyond. Annu. Rev. Physiol. 77:475-79